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Abstract
Background: Primary Sjögren syndrome (pSS) is a common autoimmune condition which primarily affects epithelial
tissue, often including the kidney causing either tubulointerstitial nephritis (TIN) or more rarely, an immune complex
related glomerulonephritis.
Methods: We describe the clinical, biochemical and histological characteristics of 12 patients with pSS related TIN and
their response to treatment with antiproliferative agents. All 12 patients were investigated and treated at the UCL
Centre for Nephrology in London.
Results: All patients had TIN demonstrated via needle biopsy; immunophenotyping showed that the interstitial
infiltrate was predominantly a CD4+ T-cell infiltrate. Urinary acidification testing demonstrated distal renal tubular
acidosis in 8 patients. Proximal tubular dysfunction was present in 5 patients. All but 1 patient were treated with
antiproliferative agents and most also with a reducing course of steroids. In the treated patients, there was a
significant improvement in the serum creatinine and measured GFR.
Conclusion: Patients with pSS TIN have significant renal impairment and other functional tubular defects. There is a
mononuclear lymphocytic infiltrate on renal biopsy and this appears to be mainly a CD4+ T-cell infiltrate. Treatment
with mycophenolate (and corticosteroids) improves the renal function in patients with pSS TIN.
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Tubulointerstitial nephritis
Background
The Swedish ophthalmologist Henrik Sjögren described
a disease characterized by oral and conjunctival dryness
(the ‘sicca syndrome’) in 1933 [1]. This disease, ‘Sjögren
syndrome’, may occur in isolation (primary Sjögren
syndrome or pSS) or secondary to other autoimmune
diseases. The epithelial inflammation that leads to failure
of lacrimal and salivary secretion can also lead to the
destruction of other epithelial tissues such as airway,
biliary, pancreatic and renal epithelia [2].
Renal disease in pSS is common; its prevalence in
some series of pSS being as high as 42 % [3].
Rarely, pSS can cause a glomerular lesion with
decreased excretory renal function and proteinuria.
The lesion itself is typically a membranoproliferative
glomerulonephritis (MPGN), but can present with a
number of other glomerular lesions (e.g. membranous
nephropathy). This is due to immune complex depos-
ition associated with B-cell expansion, cryoglobulinae-
mia and lymphoma [4, 5].
However, epithelial inflammation in pSS typically
causes tubulointerstitial nephritis, the commonest renal
lesion in pSS [6]. Although this may cause renal impair-
ment, it also causes renal tubular lesions which may be
more difficult to diagnose.
Here, we describe 12 patients with a tubulointerstitial
nephritis secondary to pSS, their demographic, biochemical,
immunological and histological characteristics along with
their response to immunosuppression.
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Methods
Patients were referred to the UCL Centre for Nephrol-
ogy tubular clinic and all underwent investigation with
serum biochemistry, immunology, and renal biopsy.
Urinary acidification testing was performed in 9 patients.
GFR was estimated in all patients using the Modification
of Renal Diet (MDRD eGFR) equation. 6 patients under-
went 3-dose 51Chromium EDTA-GFR (51Cr-GFR)
measurements before and after treatment. All patients
with pSS who underwent renal biopsy from January
2007-December 2014 were included in this analysis.
The diagnosis of pSS was based on the 2002 American
European consensus criteria [7], all patients satisfied the
same criteria; ocular and oral symptoms, positive Schirmer
test and positive Ro/La antibody status.
All patients who were suspected of having distal renal
tubular acidosis (dRTA) underwent urinary acidification
testing with a furosemide and fludrocortisone test [8] or
an ammonium chloride test [9]. Briefly, the patient is
administered either 40 mg of furosemide and 1 mg of
fludrocortisone, or 0.1 mg/kg of ammonium chloride
orally and the urine pH is monitored hourly. A fall in
the urine pH to less than 5.3 represents normal urinary
acidification; a failure to do so is diagnostic of dRTA.
Renal biopsy tissue was uniformly fixed in paraffin and
sections were stained with hematoxylin and eosin.
Immunophenotyping was performed by additional
immunostaining with polyclonal antibodies to CD3,
CD4, CD8, CD20, CD1a and CD138.
Where slides were available to review, we scored each
biopsy to assess the nature of the inflammatory cell
infiltrate and the degree of interstitial scarring. The infil-
trate was scored as being either patchy or diffuse, the
approximate amount of interstitium involved (<25 %,
25–50 %, 50–75 %, >75 %); the intensity of the infiltrate
was scored as 1+ (light), 2+ (moderate) or 3+ (heavy);
the predominant cell type in the infiltrate was recorded
as was the amount of scarring, again recorded as 1–3 +.
Patients were treated with an antiproliferative agent,
mycophenolate mofetil (MMF) or, in one case, azathio-
prine and where possible, a short reducing course of
corticosteroid. The dose of MMF was titrated according
to symptoms and recovery of renal function, and, in
hypergammaglobulinemic patients, with the aim of
bringing the IgG level within the normal range.
Statistical analysis was performed using GraphPad
Prism 5.03, statistical significance was determined using
the student’s t-test for Gaussian and Wilcoxon matched
pair signed rank test for non-Gaussian distributed data.
Ethical considerations
All patients provided written informed consent for participa-
tion in the study and ethical approval was attained from the
local ethics board (Great Ormond Street Hospital Ethics
Committee). The authors have respected participants’ rights
to privacy by de-identifying all patients data reported. By doing
so, the authors feel they have maintained anonymity and con-
fidentiality in accordance with local data protection laws.
Case vignettes
Case 1: A 54-year-old woman with pSS was referred
with impaired renal function (eGFR 28 ml/min/1.73 m2).
She complained of sicca symptoms, fatigue, urinary
frequency and nocturia. She had raised inflammatory
markers, a positive ANA, anti-Ro antibody and rheuma-
toid factor. A renal biopsy demonstrated TIN and she
was commenced on MMF 2 g/day and a reducing course
of prednisolone 30 mg. Her renal function remained
stable for 5 years but the patient unilaterally stopped her
immunosuppression; and her serum creatinine rose from
168 to 230 μmol/L. A second biopsy demonstrated TIN
with significant scarring and mild glomerular changes
(mesangial matrix expansion). Immunosuppression was
restarted with renal function settling to baseline.
Case 2: A 52-year-old woman became unwell after a
holiday in Pakistan. She presented with severe weakness,
hypokalaemia and metabolic acidosis (serum bicarbonate
12 mmol/L). She was referred for investigation of dRTA,
which was confirmed on urinary acidification testing.
On direct questioning she also reported sicca symptoms,
fatigue and arthralgia. She was ANA, anti-Ro and anti-La
antibody positive. She was treated with potassium citrate
and hydroxychloroquine 400 mg/day. She had deteriorat-
ing renal function (serum creatinine rose from 88 to
124 μmol/L) and her renal biopsy demonstrated TIN.
MMF (500 mg/day) was started resulting in improvement
in her renal function but not in her symptoms.
Case 3: A 36-year-old woman with known pSS was re-
ferred with persistent hypokalemic acidosis after elective
cholecystectomy. She had dRTA confirmed on urinary
acidification testing. There was also proximal tubular
dysfunction (phosphate wasting and low molecular
weight (LMW) proteinuria) and suggestion of a concen-
trating defect (low early morning urinary osmolality).
Renal biopsy demonstrated TIN and she was treated
with bicarbonate and potassium supplements in addition
to low dose prednisolone (5 mg/day), hydroxychloro-
quine (400 mg/day) and MMF (1 g/day). Higher doses of
MMF were prohibited by gastrointestinal side effects.
She had progressive renal dysfunction (serum creatinine
rose from 79 to 115 μmol/L) and a repeat biopsy 4 years
after the first demonstrated ongoing TIN with worse
scarring. Treatment with rituximab was attempted but
abandoned after she developed an anaphylactoid reaction.
Therefore MMF was titrated to 2 g/day and the prednisol-
one dose doubled. Despite this, she has slowly progressive
deterioration in her GFR and severe extra-renal features
(sicca symptoms, parotitis and arthritis).
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Case 4: A 45-year-old woman with known pSS was
referred with impaired renal function (eGFR 40 ml/min).
She had defective urinary acidification on testing. She
was treated with bicarbonate supplements. A renal bi-
opsy confirmed TIN. Her serum creatinine deteriorated
from 124 to 159 μmol/L and azathioprine 50 mg/day
was started. Her renal function stabilized but her sicca
symptoms remain.
Case 5: A 71-year-old woman had longstanding sicca
symptoms and chronic hypokalaemia. She presented to
hospital with diarrhea with severe hypokalaemia
(2.1 mmol/L) and paralysis. The diarrhea was due to a
colonic villous adenoma, for which she underwent a
hemicolectomy. She was referred to our service for her
hypokalaemia which persisted after her surgery. She
reported sicca symptoms, arthralgia and systemic upset
with associated positive pSS serology. dRTA was
confirmed by urinary acidification testing. She under-
went renal biopsy which demonstrated TIN with heavy
staining for C9 along tubular basement membranes
(negative staining for immunoglobulin). Potassium and
bicarbonate supplements were commenced along with
prednisolone 20 mg/day and hydroxychloroquine
200 mg/day. She was intolerant of both of these
(dyspepsia and rash respectively) and developed wors-
ening renal function off immunosuppression (serum
creatinine rose from 97 to 159 μmol/L). MMF (1 g/day)
was introduced with resolution of her renal impairment
and improvement in her extra-renal symptoms.
Case 6: A 54-year-old woman was referred having
passed a pure calcium phosphate stone, suggestive of
dRTA. She had renal impairment (eGFR 32 ml/min/
1.73 m2), imaging which demonstrated multiple stones
bilaterally, and a long history of sicca symptoms with
systemic upset. Her pSS serology was positive, she had
dRTA confirmed on urinary acidification testing and had
evidence of proximal tubular dysfunction (LMW protein-
uria). A renal biopsy demonstrated TIN. She was treated
with potassium citrate, a reducing course of prednisolone,
MMF 1 g/day, and hydroxychloroquine 200 mg/day. Con-
sequently, her renal function and symptoms improved.
Case 7: A 48-year-old woman presented to her GP
with tiredness. She was found to have renal impairment
(eGFR 39 ml/min/1.73 m2) and nephrocalcinosis. On
direct questioning, she reported sicca symptoms and a
rash. Her pSS serology was positive and she underwent
renal biopsy, which demonstrated TIN with areas of
calcification. She also had an incidental finding of thin
glomerular basement membranes on electron microscopy.
She had a systemic acidosis with an inappropriately high
urinary pH, confirming dRTA. She was treated with
potassium and bicarbonate supplementation, low dose
steroid and MMF 500 mg/day; her renal function and
symptoms improved.
Case 8: A 43-year-old woman was referred to our center
with renal impairment (eGFR 36 ml/min/1.73 m2) and
nephrocalcinosis. She reported longstanding sicca symp-
toms with systemic upset. She was acidotic (serum bicar-
bonate 18 mmol/L) and hypokalemic (2.8 mmol/L), and
had dRTA confirmed by urinary acidification testing. She
also had proximal tubular dysfunction (phosphate wasting
and LMW proteinuria) and serology for pSS was positive.
Renal biopsy demonstrated TIN with positive staining for
C9 along tubular basement membranes. She was treated
with potassium citrate supplements, a reducing course of
prednisolone, and MMF 1.5 g/day. Her renal function
stabilized, her electrolytes normalized, and her extra renal
symptoms substantially improved.
Case 9: A 51-year-old woman was referred with unex-
plained renal impairment (eGFR 30 ml/min/1.73 m2).
She had a long history of dry eyes for which she had
been using artificial tears. pSS serology was positive and
she underwent renal biopsy which demonstrated TIN.
Subsequent urinary acidification testing demonstrated
dRTA. She was treated with a reducing course of prednis-
olone and MMF 1.5 g/day. Her renal function improved
but her sicca and non-specific symptoms persisted.
Case 10: A 61-year-old woman was referred with renal
impairment (eGFR 43 ml/min/1.73 m2). She was non-
specifically unwell with positive pSS serology and sicca
symptoms. She underwent renal biopsy, which demon-
strated TIN, and she was treated with a weaning course
of prednisolone. Renal function was stable for 4 years off
treatment but underwent further renal biopsy to reassess
interstitial inflammation. This showed ongoing areas of
TIN with increased chronic damage when compared to
the initial biopsy. Immunosuppression with both MMF
500 mg/day and subsequently azathioprine 75 mg/day
has been complicated by anemia and leucopenia. A bone
marrow aspiration and biopsy revealed myelodysplastic
changes only. She remains off immunosuppression
currently with stable renal function (eGFR 45 ml/min/
1.73 m2) and limited symptoms.
Case 11: A 72-year-old woman with longstanding sys-
temic upset and arthralgia was initially misdiagnosed
with rheumatoid arthritis. She subsequently developed
impaired renal function (eGFR 46 ml/min/1.73 m2). She
had mild sicca symptoms and her pSS serology was
positive; a renal biopsy demonstrated TIN with C9
staining along tubular basement membranes. She was
treated with MMF 1 g/day. Renal function improved as
did her symptoms.
Case 12: A 53-year-old man was admitted with a painful
peripheral neuropathy. He complained of sicca symptoms,
was found to have renal impairment (eGFR 50 ml/min/
1.73 m2), and developed a vasculitic rash. Cryoglobulins
were present, there was hypocomplementaemia, pSS
serology was positive, and a renal biopsy demonstrated
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TIN with mild mesangial proliferation. He was treated with
a reducing course of prednisolone (initially 40 mg/day) and
MMF 1 g BD. His renal function improved and his symp-
toms have settled.
Results
The series encompasses twelve patients, 11 of these are
female, with a median age of 52.5 (interquartile range
(IQR) 13.5 years). At presentation the patients tended
toward a metabolic acidosis (median serum bicarbonate
21 mmol/L, IQR 5.75), and had moderate renal impair-
ment (median serum creatinine 133 μmol/L, IQR 53.2),
but little or no hypokalaemia (median serum potassium
4.2 mmol/L, IQR 1.25).
The diagnosis of pSS was not known in 8 (66 %) patients
prior to investigation of their renal impairment. All
patients were Ro positive and 61 % were La positive.
Rheumatoid factor was raised in 67 % (median 388 IU/L,
IQR 630.8), complement factors C3 and C4 were
preserved (median 108 and 16.0 mg/dL, IQR 49 and 6,
respectively) and there was hypergammglobulinemia at
presentation in 70 % (median IgG 19.8 g/L, IQR 10) and
the erythrocyte sedimentation rate tended to be high
(median 50 mm/h, IQR 72.75) (Table 1).
9 patients had urinary acidification testing with
furosemide and fludrocortisone or ammonium chloride.
All but two of nine patients had abnormal urinary
acidification, indicating dRTA (median baseline urine
pH 6.24, IQR 1.3; median nadir urine pH 5.77, IQR
0.91); of the remaining two, one had an equivocal result
(Fig. 1). A further 2 patients had a systemic acidosis and
an inappropriately alkaline pH at baseline. Overall, 75 %
had evidence of abnormal urinary acidification.
Proximal tubular dysfunction was assessed in 8 patients
by measuring urinary retinol binding protein (RBP). The
urinary RBP/Creatinine ratio was abnormally high in 5
patients (median 102 μg/mmol, IQR 1867, normal range
4–32 μg/mmol), and 2 patients had extremely high ratios
(as high as 5885 μg/mmol).
All patients underwent a renal biopsy. Histology
revealed a tubulointerstitial nephritis in all patients. Of
the 14 biopsies performed in this series, 11 were avail-
able for us to review the tissue in addition to having the
formal report.
The inflammatory cell infiltrate was diffuse in two
of the biopsies and patchy in the remainder, and the
intensity was rated as 1+ (light) in 5, 2+ (moderate)
in 5 and 3+ (heavy) in 1. The proportion of interstitium
affected by the infiltrate was <25 % in 3, 25–50 % in 2,
50–75 % in 2 and >75 % in 4. In all cases the predominant
cell type was mononuclear lymphocytes. Scarring was
judged to be 1+ (light) in 6, 2+ (moderate) in 4, and 3+
(heavy) in 1.
Thus, the infiltrate tended to be patchy, light to
moderate in intensity and to affect the majority of
the interstitium. Interstitial scarring was judged to be
light to moderate (Fig. 2 for representative histology).
Three patients also had coexisting glomerular disease;
one was coincidental thin basement membrane disease
found on electron microscopy, the remaining two had
mild glomerular mesangial matrix expansion.
Immunophenotyping revealed that the inflammatory
interstitial infiltrate was a T-cell infiltrate, and was pre-
dominantly CD4+, with lesser amounts of CD8+ cells
and almost no CD20+ B-cells (see Fig. 3 for representa-
tive pictures).
Of the 12 patients, 11 were treated with MMF (median
dose 1000 mg/day, 1000–1500 mg), 2 were treated with
azathioprine (median dose 62.5 mg/day) and 1 had no
immunosuppressive treatment at all. 9 patients were treated
with Prednisolone (median starting dose 10 mg/day, 5–
20 mg) weaned over 3–6 months. 4 patients remain on low
dose Prednisolone (median dose 7.5 mg/day, 5–10 mg) in
conjunction with MMF. The median duration of immuno-
suppressive treatment was 24 months (IQR 24).
Both serum creatinine and eGFR improved following
treatment; the median serum creatinine decreased
significantly following immunosuppression treatment
(153 μmol/L, IQR 25, to 124 μmol/L, IQR 39, p = 0.02),
as did the eGFR (32mls/min/1.73 m2, IQR 12 to 42mls/
min/1.73 m2, IQR 21, p = 0.04). The GFR was directly
measured in 6 patients, which also improved following
treatment (37mls/min/1.73 m2, IQR 10.5, to 46mls/min/
1.73 m2, IQR 6.5, p = 0.04). Serum IgG levels decreased
significantly following treatment (20.1 g/L, IQR 7.1 to
17.3 g/L, IQR 8.8, p = 0.01) (Fig. 4).
Discussion
Primary Sjögren syndrome has been estimated to affect
0.6 % of the US population (1.3 million US adults) [10]
and has a worldwide distribution with consistent clinical
characteristics [11].
Data on the prevalence of renal disease in pSS comes
from two sources; retrospective studies looking for overt
renal dysfunction, mainly defects in excretory renal
function and proteinuria [5, 12, 13], and smaller pro-
spective series in which tubular defects were explicitly
screened for [3, 14–16]. While the retrospective studies
found a rate of renal involvement in pSS of 4.3–6.5 %
[5, 12, 13], the prospective studies observed a much
higher rate of 28–42 % [3, 15].
The rarer glomerular lesions, typically the characteris-
tic membranoproliferative glomerulonephritis (MPGN),
occur due to immune complex deposition following
B-cell expansion. These immune complexes are often
cryoglobulins [5], which bind to vascular endothelium
and may cause a small vessel vasculitis. This clinical
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Table 1 Demographic, biochemical and immunological data for the 12 patients with pSS
Patient Age Sex Presentation/
reason for
referral
Extra-renal
clinical
features
ANA Anti-Ro Anti-La RF (0–
20
IU/ml)
C3 (70–
165
mg/dL)
C4 (16–
54
mg/dL)
IgG (7-
16
g/L)
Serum
protein
electrophoresis
ESR
(mm/hr)
Creatinine
(μmol/L)
Urine PCR
(mg/mmol)
1 54 Female Renal impairment
Urinary Symptoms
Sicca, Non-specific
(generally unwell,
fatigue, poor energy)
positive
(>1/1000 fine
speckled)
Positive Negative 145 128 15 24.9 Polyclonal
increase in
immunoglobulins
107 168 0
2 52 Female Hypokalaemic
acidosis with
paralysis
Sicca, Non-specific
(generally unwell,
fatigue, poor energy),
arthralgias
positive
(>1/1000 fine
speckled)
Positive Positive N/A 137 29 27.5 Polyclonal
increase in
immunoglobulins
88 97 27
3 36 Female Hypokalaemic
acidosis
Sicca, Non-specific
(generally unwell,
fatigue, poor energy),
arthralgias, parotitis,
low mood.
positive
(>1/1000 fine
speckled)
Positive Positive 718 148 21 24.8 Polyclonal
increase in
immunoglobulins
35 88 102
4 45 Female Renal impairment Sicca positive
(>1/1000 fine
speckled)
Positive Positive 743 139 15 37.6 Polyclonal
increase in
immunoglobulins
121 124 N/A
5 71 Female Hypokalaemic
acidosis with
paralysis
Sicca, Non-specific
(generally unwell,
fatigue, poor energy),
arthralgias
positive
(>1/1000 fine
speckled)
Positive Negative 618 124 21 21.3 Polyclonal
increase in
immunoglobulins
86 106 101
6 54 Female Renal impairment
Stones
Sicca, Non-specific
(generally unwell,
fatigue, poor energy)
positive
(>1/1000 fine
speckled)
Positive Positive 69 89 16 18.5 N/A 5 186 50
7 48 Female Renal impairment
Nephrocalcinosis
Sicca, Non-specific
(generally unwell,
fatigue, poor energy),
rash
positive
(>1/1000 fine
speckled)
Positive Positive 93 N/A N/A 14 Polyclonal
increase in
immunoglobulins
33 133 127
8 43 Female Renal impairment
Nephrocalcinosis
Sicca, Non-specific
(generally unwell,
fatigue, poor energy)
positive
(>1/1000 fine
speckled)
Positive Positive <20 108 21 19.7 Polyclonal
increase in
immunoglobulins
N/A 141 46
9 51 Female Renal impairment Sicca, Non-specific
(generally unwell,
fatigue, poor energy)
positive
(>1/1000 fine
speckled)
Positive Negative <20 70 16 19.9 N/A 5 168 0
10 61 Female Renal impairment Sicca, non-specific
(generally unwell,
fatigue, poor energy)
positive
(>1/1000 fine
speckled)
Positive Positive 158 85 20 13.7 Polyclonal
increase in
immunoglobulins
25 115 0
11 72 Female Renal impairment Sicca, non-specific
(generally unwell,
fatigue, poor energy),
arthralgia and GI upset.
positive
(>1/1000 fine
speckled)
Positive Negative N/A 88 14 17.6 Paraprotein with
immunoparesis
N/A 133 N/A
12 53 Male Renal impairment Sicca, neuropathy,
vasculitic rash,
cryoglobulinaemia
positive
(>1/1000 fine
speckled)
Positive Negative 1370 96 3 12.4 Type 1
IgM kappa
cryoglobulin
65 133 40
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picture occurs with clonal B-cell expansion, is usually
associated with lymphoma, and tends to occur late in
the course of the disease [4, 5].
The more typical tubulointerstitial nephritis can mani-
fest in a number of ways, including with a mild to moder-
ate reduction in the glomerular filtration rate, although
progression to end stage renal failure with pSS TIN is
reported [5]. The tubular dysfunction can manifest as
proximal tubular dysfunction with low molecular weight
proteinuria [3] or a full-blown renal Fanconi syndrome
[17] (with bicarbonaturia, uricosuria, phosphaturia, glyco-
suria and low molecular weight proteinuria). Distal tubular
disease may cause the characteristic distal renal tubular
acidosis [18] (with hypokalaemia, nephrocalcinosis/kidney
stones, osteomalacia and a variable metabolic acidosis) or
nephrogenic diabetes insipidus [19] (NDI).
These tubular lesions often require special investigations
to diagnose; assays for low molecular weight proteinuria
(e.g. retinol binding protein), urinary acidification tests to
diagnose dRTA and water deprivation tests to diagnose
NDI may not be available outside of specialist centres.
We would advocate renal biopsy in all patients with
pSS and tubular defects to confirm the diagnosis of TIN,
and to distinguish from other potential causes of local-
ised tubular defects (eg. the presence of light chain).
The TIN of pSS is characterized by an invasion of
mononuclear lymphocytes. We found that these cells are
predominantly CD4+ T-cells with lesser populations of
CD8+ T-cells; this is in keeping with data from mouse
models of renal pSS [20] as well as data in human renal
tissue [21], although one study suggested that CD8+
T-cells are more dominant [22].
Fig. 1 Demonstrates distal and proximal tubular dysfunction. Panel a
shows urinary acidification tests. Baseline and nadir urine pH values are
shown. The dotted line represents the threshold urine pH of 5.3 that
determines normal urinary acidification. Panel b shows urinary RBP/
creatinine ratio. The dotted line shows the upper limit of normal
(32 μg/mmol)
Fig. 2 These panels are of representative hematoxylin and eosin stained slides from 2 patients showing the typical mononuclear lymphocytic
inflammatory infiltrate of pSS TIN. Panels a & b are x10 magnification, panel c is x20 and panel d is x40 magnification
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This pattern of epithelial inflammation is strikingly
similar to that seen in labial salivary glands (LSGs),
which are much more intensively studied. There is
evidence that the infiltrating CD4+ T-cells may be
pathogenic Th17 cells; IL-17 levels are elevated in the
salivary glands and serum of pSS patients and these
levels correspond to the severity of the histological
lesion [23]. Furthermore, knocking out IL-17 prevents
disease in a mouse model of Sjögren syndrome [24]. In
more extensive histological disease in LSGs, B-cells
become more pronounced in the infiltrate, and it has
been suggested that treatment could be tailored to the
type of infiltrating cell [25].
However, there are no proven effective systemic
immunosuppressive treatments for pSS; the few ran-
domized trials have been inconclusive or contradictory.
Typical treatment for patients with joint or skin
disease with pSS, is often based on hydroxychloroquine
or methotrexate. Resistant or extraglandular disease has
been treated variously with corticosteroids, antiprolifera-
tive agents, calcineurin inhibitors, cyclophosphamide or
B-cell depletion therapy [26].
The patients in this series were all treated with MMF;
the rationale being that MMF would affect both T-cell
and B-cell populations and should therefore be effective
across the spectrum of pSS TIN. Indeed, MMF has been
used successfully with acute TIN in other settings [27].
The optimal dose of MMF to use is unknown and the
dose of MMF used in our series was relatively low. We
adopted a pragmatic approach and escalated the MMF
in the presence of persistent symptoms, or failure of
recovery of renal function. We aimed where possible to
normalise the serum IgG, as there is a well-recognised
association between hypergammaglobulinaemic states
and dRTA (originally reported by Morris and Fudenberg
[28]) and TIN, even in the context of idiopathic hyper-
gammaglobulinaemia [29]. We also used a short weaning
course of corticosteroids, if there was no contraindi-
cation to do so, as suggested by two previous series
[17, 30]. This regime was well tolerated, with only
one patient unable to continue with MMF due to
reversible leucopenia.
We have demonstrated a significant improvement in
the MDRD eGFR in the patients treated in this way; this
is the first series to do so in pSS TIN alone. That the
measured 51Cr-GFR in 6 of these patients significantly
improved suggests that this effect is real. Two other
series have shown variable improvement in excretory
renal function using corticosteroids and various immuno-
suppressants in a cohort that included both TIN and
MPGN patients [17, 30]. We suspect that specific tubular
defects occur relatively early within the disease process
and during the stage of active inflammation. We aim to
abrogate this inflammation prior to the development of
significant fibrosis, and progressive renal disease.
Limitations
This is a retrospective description of a relatively small
number of patients from a single centre, and as such,
there is no control population, and the investigations
and treatment regimes are not completely uniform. As it
is a description of pSS patients with TIN, the results are
not necessarily generalisable to all patients with pSS.
Fig. 3 Shows representative pictures of slides immunostained for lymphocyte markers from the same patient. Panel a is stained for the T-cell
marker CD3, panel b is stained for CD4, panel c is stained for CD8, and panel d is stained for the B-cell marker CD20
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Conclusion
Patients with pSS TIN present with significant renal
impairment and frequent tubular defects. The lesion is
characterized by a mononuclear lymphocytic infiltrate
that is predominantly composed of CD4+ T-cells and
subsequent scarring. Treatment with MMF with or with-
out a course of oral corticosteroids improved excretory
renal function. Further studies into the pathogenesis and
treatment of pSS TIN are warranted, given the frequency
of this disease. Furthermore such studies may bring
valuable insights into other inflammatory processes in
the renal interstitium, such as acute allergic TIN and
renal allograft rejection.
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